Observational Analysis of the Influence of Medical Marijuana Use on Quality of Life in Patients.

Introduction: A significant gap exists in the understanding and utilization of medical marijuana and its effects on a patient's quality of life. This is largely attributed to Cannabis' sp. Schedule 1 classification, which has impeded the scientific investigation of its effects on the endocannabinoid system (ECS) and quality of life. Additionally, conflicting results from previous studies highlight the need for more research to provide guidance to both patients and clinicians regarding the therapeutic potential of medical marijuana. Methods: Patients over 18 years of age who were members of the Pennsylvania Medical Marijuana Program (PAMMP) were recruited from regulated Pennsylvania medical marijuana dispensaries. Eligible patients were enrolled through informed consent, following a study design that received approval from the LECOM Institutional Review Board (IRB). Over 90 days, participants were remotely administered an electronic survey every 30 days to collect medical marijuana use patterns and assess changes in quality of life. Results: Of the 103 participants who completed the study, significant improvements were observed in physical and social functioning, emotional well-being, and energy levels within the first 30 days. Participants reported significant decreases in emotional limitations, fatigue, and pain levels. Notably, participants who used inhaled or vaped products (defined as vape cartridges and concentrates) were younger and exhibited a significantly higher increase in emotional well-being scores compared to those who used flower products (defined as dry leaf only). Participants who consumed medical marijuana for opioid use demonstrated significantly higher THC consumption compared to those seeking treatment for anxiety, chronic pain, or inflammatory bowel disease (IBD). Improvements in the first 30 days also remained constant for the remainder of the study. Discussion: This study contributed valuable insights into the effects of medical marijuana on quality of life and highlighted potential benefits associated with its use. Moreover, ongoing research aims to assess the observed sustained improvements beyond 90 days, investigating potential long-term trends. While further research is needed to explore the underlying mechanisms of action and long-term effects of medical marijuana, clinicians and patients can gain a better understanding of medical marijuana's therapeutic potential, enabling more informed decisions regarding its use in clinical settings.

This research looks at the effects of medical marijuana on a patient's quality of life. The study involved 103 participants from Pennsylvania who were using medical marijuana for various health conditions. They answered four surveys over 90 days, reporting on their experiences with marijuana and their well-being. The results showed that many participants experienced improvements in their physical and social functioning, energy levels, and emotional well-being within the first 30­60 days of using medical marijuana. Interestingly, the study found that how often someone used medical marijuana could affect their overall health. Those who used it once a day tended to have better general health scores compared to those who used it more frequently. Alcohol use seemed to have an impact too. People who used both alcohol and medical marijuana had lower energy levels and emotional well-being, suggesting that the combination might not be ideal. The study also looked at how people consumed medical marijuana, whether by inhaling it or using it as a flower, and found differences in THC consumption and emotional well-being. However, the study had some limitations, like relying on self-reported data and having a small sample size. Still, it provides valuable insights into how medical marijuana can affect people's lives and highlights the need for personalized approaches to its use.

Pancreaticocolonic fistulas secondary to severe acute pancreatitis treated by percutaneous drainage: successful nonsurgical outcomes in a single-center case series.

PURPOSE: Pancreaticocolonic fistulas (PCFs) are uncommon complications of acute necrotizing pancreatitis (ANP). Studies advocating primary surgical treatment showed severe morbidity and mortality with nonsurgical treatment, with survival rates of approximately 50%. However, a nonsurgical treatment scheme with primary percutaneous drainage and other interventions may show improved outcomes. This retrospective single-center study describes the presentation, diagnosis, course, treatment strategy, and outcome of successfully treated PCFs, with an emphasis on nonsurgical interventions. MATERIALS AND METHODS: Twenty patients with PCFs caused by ANP were treated with percutaneous drainage and medical therapy. Additional interventions included endoscopic transenteric drainage and pancreatic duct (PD) stent placement. Surgery was reserved for patients in whom this nonsurgical management failed. RESULTS: All PCFs closed during a median follow-up of 56 days (mean, 106 d; range, 13-827 d). Treatment included percutaneous drainage of the PCF-related collection in all patients, PD stents in 60%, transenteric drainage in 15%, and definitive surgery in 15%. Indications for surgery included severe PCF-related symptoms, large feculent peritoneal collection, and colonic stricture. Two patients (10%) died, one of complications of ANP and one of esophageal carcinoma. Additional enteric fistulas were identified in 50% of patients. Median time from the most recent diagnosis of pancreatitis to PCF diagnosis was 89 days (mean, 113 d; range, 13-394 d). CONCLUSIONS: A nonsurgical approach to PCFs caused by ANP, including percutaneous drainage and other techniques, yields good survival, with surgery reserved for cases in which this approach fails.

Evaluation of three polytetrafluoroethylene stent-grafts in a model of neointimal hyperplasia.

PURPOSE: The authors tested three different porosities of expanded polytetrafluoroethylene (ePTFE)-covered stents and bare stents by using an animal model of restenosis. MATERIALS AND METHODS: Both iliac arteries in 18 female pigs were injured by overdilating 20-mm-long angioplasty balloons. A 40-mm-long bare stent or one of three 44-mm-long ePTFE-covered stents was deployed at the injury site. To determine restenosis, neointimal area measurements were made with intravascular ultrasonography. Histologic analyses were performed at an independent laboratory to determine neointimal attachment. RESULTS: Neointimal area was greatest at the middle of the bare stent, where balloon injury was centered. When the middle location of the covered stents was evaluated, the neointimal area of both the medium- and high-porosity covered stents was smaller than that of the matched control stents (P = .0018 and P = .0118, respectively). The neointimal area of the low-porosity covered stents was similar to that of the bare stents. Histologic study showed dehiscence of the neointima of the low-porosity covered stents. CONCLUSIONS: The microstructure of the low-porosity covered stents did not provide a suitable surface for neointimal attachment and did not reduce neointimal growth compared to that with the control stents. The microstructure of the medium- and high-porosity covered stents yielded less neointimal growth than both the control stents and the low-porosity covered stents without evidence of neointimal dehiscence. The authors believe that covered stents made with ePTFE with either medium or high porosity could limit restenosis in humans compared to that with bare stents.